Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance
Clinical trial NCT04785729 · UNKNOWN
Trial details
- NCT number
- NCT04785729
- Sponsor
- Sun Yat-sen University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-31
- Primary completion
- 2023-12-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.